Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Pharmacy at Karmanos Cancer Center

Actemra

Afinitor

Alecensa

Alunbrig

Aranesp

Benlysta

Bosulif

Braftovi

Cabometyx

Cosentyx

Enbrel

Erleada

Gilotrif

Ibrance

Ilumya

Imbruvica

Inlyta

Iressa

Jakafi

Kesimpta

Koselugo

Lenvima

Lonsurf

Lorbrena

Lynparza

Mayzent

Mekinist

Mektovi

Nerlynx

Nexavar

Nplate

Nubeqa

Ofev

Olumiant

Piqray

Promacta

Qinlock

Retevmo

Revlimid

Rozlytrek

Stelara

Sutent

Tabrecta

Tafinlar

Tagrisso

Talzenna

Tarceva

Tasigna

Tavalisse

Tecfidera

Temodar

Tibsovo

Tykerb

Venclexta

Verenzio

Vizimpro

Votrient

Xalkori

Xolair

Xpovio

Xtandi

Zejula

Zelboraf

Zydelig

Zykadia

Rinvoq | Pharmacy at Karmanos Cancer Center

Which health plans does Pharmacy at Karmanos Cancer Center have contracts with?

Does Pharmacy at Karmanos Cancer Center work closely with Rinvoq and AbbVie Inc.?

Does Pharmacy at Karmanos Cancer Center offer services for Rinvoq patients?

What conditions does Pharmacy at Karmanos Cancer Center support?

How does Pharmacy at Karmanos Cancer Center help with insurance?